argenx SE (ARGX) Up 5.4% — Is This a Buying Opportunity?

  • ARGX rose 5.42% to $870.36 from $825.61 the previous trading day
  • Weiss Ratings assigns C (Hold)
  • Market cap is $51.20B

argenx SE (ARGX) is pushing sharply higher on Tuesday, last changing hands at $870.36 on the NASDAQ, a $44.75 gain over the prior close of $825.61. The advance gives the stock meaningful room to work with. ARGX sits roughly 18.9% below its 52-week high of $1,072.75, set on September 2, 2026, and about 31.5% above the bottom of its 52-week range at $661.85. With the stock having already given back a substantial portion of its late-summer peak, today's rally offers investors a fresh look at a name with a full calendar of catalysts directly ahead.

Volume stands at approximately 142,018 shares so far in the session, compared with a 90-day average of roughly 338,321. That puts turnover at about 42% of a typical full day's activity with the regular session still underway.


Why argenx SE Price is Moving Higher

This is a company-specific repricing, not a sector tide. The Biotech ETF (XBI) was trading near $147.92 against a $147.86 prior close, essentially flat, while ARGX outran large-cap peers such as Merck & Co., Inc. (MRK), up 3.00%, and Regeneron Pharmaceuticals, Inc. (REGN), up 1.86%. The clearest same-day spark came from Oddo BHF, which raised its price target on argenx to €875 from €855 and reiterated its Outperform rating. The bullish call carried through in Europe as well, where argenx's shares climbed about 5% even as the CAC 40 and SBF 120 each slipped roughly 0.6%. Elsewhere on the Street, RBC trimmed its target to $1,025 from $1,100 but kept its Outperform rating. Even after that cut, RBC's target implies more than 17% upside from the current price.

The timing is just as important as the analyst call. argenx is scheduled to report Q3 results on October 22, and investors are positioning ahead of that print after a dominant second quarter. Q2 revenue reached $1.54 billion against the $1.45 billion consensus, and diluted EPS of $7.32 beat the $5.86 estimate by a wide margin. Product sales grew 60% year over year, and net profit nearly doubled to $472 million from $245 million. That kind of commercial momentum sets a high bar for Thursday's report, and today's buying signals confidence that VYVGART demand can clear it.

The pipeline is adding fuel. In August, argenx reported positive Phase 3 ALKIVIA results for efgartigimod in myositis. The drug beat placebo by 15.4 points on the 52-week improvement score, 47.95 versus 32.56, with a p-value of 0.0011. On October 19, the company confirmed that the detailed data will be presented on November 11. That gives investors two meaningful events within a month: earnings this week and a full clinical readout in a potential new indication shortly after.


What is the argenx SE Rating - Should I Buy?

Weiss Ratings assigns ARGX a C rating. The rating was downgraded on 7/23/2026. Current recommendation is Hold. The downgrade landed on the same day argenx posted its blowout second quarter. That timing shows the rating weighs the stock's full risk/reward picture, including valuation and price behavior, rather than one quarter's results alone. A C rating means Hold, and for a company with this much commercial and clinical momentum, it frames ARGX as a name with real upside that investors should watch closely.

The balance sheet and operating profile are where argenx stands out. The Excellent rating on the Solvency Index reflects a company that has crossed into strong, self-funding profitability. A biotech that grows net income from $245 million to $472 million in a single year can finance a broad late-stage pipeline without leaning on dilutive capital raises. The Good rating on the Efficiency Index carries the same message. Trailing EPS of $15.33 shows argenx converting VYVGART's commercial scale into real earnings power, an uncommon achievement for a company that only recently moved past the development stage.

Where the picture becomes more nuanced is in the three indices rated Fair. The Growth Index rating looks conservative next to 59.36% revenue growth and a 17.8% sequential revenue gain in the latest reported quarter. The rating suggests the Weiss framework is weighing how durable that pace is for a business still concentrated in the efgartigimod franchise. A forward P/E of 53.87 shows how much of that growth the market already expects. The Fair ratings on the Total Return Index and the Volatility Index reflect the stock's recent path. ARGX ran to $1,072.75 in early September, pulled back nearly 19%, and is now rebounding more than 5% on a single analyst upgrade and pre-earnings positioning. Those swings explain why neither index is rated higher. They also explain why the stock can reward investors who time their entries around catalysts.

Within the Health Care sector, argenx is on par with Merck & Co., Inc. (MRK, C), Gilead Sciences, Inc. (GILD, C), and Regeneron Pharmaceuticals, Inc. (REGN, C). argenx brings faster top-line growth than any of those established names. That makes it the higher-octane choice within the same risk/reward tier.


About argenx SE

argenx SE (ARGX) is a commercial-stage biopharmaceutical company in the Health Care sector. Founded in 2008 and based in Amsterdam, the Netherlands, argenx develops therapies for autoimmune diseases and markets them in the United States, Japan, China, the Netherlands, and other international markets. Its flagship product, VYVGART, treats generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP). The subcutaneous formulation, VYVGART HYTRULO, is approved for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).

The company's strategy centers on efgartigimod, its neonatal Fc receptor (FcRn) blocker, which argenx is advancing across a broad set of immunology indications. These include seronegative gMG, ocular myasthenia gravis, primary ITP, Graves' disease, myositis, Sjögren's disease, systemic sclerosis, and antibody-mediated rejection. Beyond efgartigimod, argenx is developing empasiprubart for multifocal motor neuropathy, delayed graft function, and CIDP, and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. Its earlier-stage portfolio includes ARGX-213, an FcRn-targeted antibody engineered for half-life extension and sustained IgG reduction, along with ARGX-124, the IL-6-targeting ARGX-109, the immunoglobulin A-targeting ARGX-121, and ARGX-118, which targets Galectin-10.

argenx's competitive edge comes from its leadership in FcRn biology and its "pipeline-in-a-product" approach. Each new indication for efgartigimod builds on established safety data and commercial infrastructure. Strategic partnerships extend that reach. Zai Lab develops and commercializes efgartigimod in Greater China, Halozyme's ENHANZE technology powers the subcutaneous VYVGART HYTRULO, and the company holds licensing arrangements with OncoVerity for cusatuzumab and AbbVie for ARGX-115.


Investor Outlook

argenx SE (ARGX) carries a Weiss Rating of C (Hold). It backs that rating with surging product sales, strong profitability, and a dense near-term catalyst calendar that gives patient investors plenty to work with. The October 22 Q3 report will show whether VYVGART can sustain the roughly 60% growth seen in Q2. The November 11 presentation of the full ALKIVIA data in myositis could open another major indication for efgartigimod. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.

--

This Weiss Instant News Alert was compiled by narrative data technology, our proprietary ratings models and analysis by Weiss Ratings with the intent of providing our readers with the fastest research and independent coverage. Weiss Instant News Alerts have been reviewed by a member of our editorial staff before publication. Please send any questions or comments about this story to [email protected]
Top Tech Stocks
See All »
B
AAPL NASDAQ $352.45
B
MSFT NASDAQ $508.29
B
NVDA NASDAQ $150.96
Top Consumer Staple Stocks
See All »
B
WMT NASDAQ $127.36
B
Top Financial Stocks
See All »
B
A
JPM NYSE $324.11
B
V NYSE $415.22
Top Energy Stocks
See All »
B
CVX NYSE $205.88
B
COP NYSE $134.40
Top Health Care Stocks
See All »
B
LLY NYSE $1,382.75
B
JNJ NYSE $272.70
B
ABBV NYSE $286.01
Top Real Estate Stocks
See All »
B
PLD NYSE $125.22